New lung cancer treatment launches
The drug, plus chemotherapy, shows a significant survival benefit.
A new drug to treat extensive-stage small cell lung cancer (ES-SCLC) is launching in the U.S.
AstraZeneca recently garnered FDA approval for durvalumab (Imfinzi) as a first-line treatment for adult patients with ES-SCLC in combination with standard-of-care (SoC) chemotherapies, etoposide and either carboplatin or cisplatin (platinum-etoposide).
Related: Lung Cancer Drug Snags Priority Review
SCLC is a highly aggressive, fast-growing form of lung cancer that typically recurs and progresses rapidly despite initial response to chemotherapy. Imfinzi is the only immunotherapy “to show both a significant survival benefit and improved response rate in combination with chemotherapy for these patients, an important step forward in treating this devastating disease,” AstraZeneca says in a press release.
FDA’s approval was based on the Phase 3 CASPIAN trial showing Imfinzi in combination with SoC platinum-etoposide demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus SoC alone.
In the IMFINZI plus SoC arm, the risk of death was reduced by 27% with median overall survival of 13 months versus 10.3 months for SoC alone. There was also an increased confirmed objective response rate in the Imfinzi plus SoC arm (68% versus 58% for SoC alone).
Related: Small Molecular Drugs Led 2019 Approvals
“Patients with extensive-stage small cell lung cancer continue to face a poor prognosis, and finding new medicines to improve outcomes in this setting has been a formidable challenge. The CASPIAN trial enables clinicians to choose durvalumab in combination with etoposide and either carboplatin or cisplatin, making this an important new first-line treatment option for patients that is both effective and well-tolerated,” says Jonathan Goldman, MD, associate professor of hematology & oncology at UCLA Medical Center and a lead investigator in the CASPIAN trial.
The most common adverse reactions to Imfinzi were nausea, fatigue/asthenia and alopecia.
Read more: FDA Clears Novel Generic Thyroid Cancer Treatment
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
